Goldline Pharmaceutical IPO open date is May 12, 2026 and the IPO will close on May 14, 2026. Goldline Pharmaceutical IPO is a Book build Issue. The company to raise around ₹11.61 crores via IPO that comprises fresh issue of ₹11.61 crores and offer for sale up to [.] equity shares with face value of ₹10 each.
Goldline Pharmaceutical IPO price band is ₹41 to ₹43 per share. The retail quota is 35%, QIB is 50%, and HNI is 15%. Goldline Pharmaceutical IPO to list on BSE SME on May 19, 2026. The allotment of Goldline Pharmaceutical IPO date is May 15, 2026.
The company reported revenue of ₹28.06 crores in 2025 against ₹23.57 crores in 2024. As per the financials the IPO investors should apply the IPO for a long term.
Goldline Pharmaceutical Subscription
Last updated on 13-May-2026 10:15:12
| Category | Offered | Applied | Times |
|---|---|---|---|
| QIBs | 540000 | 705000 | 1.31 |
| HNIs | 390000 | 14892000 | 38.18 |
| bHNI | 260000 | 9834000 | 37.82 |
| sHNI | 130000 | 5058000 | 38.91 |
| Individual | 900000 | 39504000 | 43.89 |
| Total | 1830000 | 55101000 | 30.11 |
| Application-Wise Breakup | |||
|---|---|---|---|
| Category | Reserved | Applied | Times |
| HNIs (10L+) | 29 | 342 | 11.79 |
| HNIs (3-10L) | 14 | 515 | 36.79 |
| Individual | 150 | 6584 | 43.89 |
| QIB Interest Cost Per Share (7 Days) | |||||
|---|---|---|---|---|---|
| @7% ₹0.1 | @8% ₹0.1 | @9% ₹0.1 | @10% ₹0.1 | @11% ₹0.1 | @12% ₹0.1 |
Goldline Pharmaceutical Lot(s) Distribution
| Category | Lot(s) | Qty | Amount | Reserved |
|---|---|---|---|---|
| INDIVIDUAL | 2 | 6000 | 258000 | 150 |
| sHNI | 3 | 9000 | 387000 | 14 |
| bHNI | 8 | 24000 | 1032000 | 29 |
Goldline Pharmaceutical Reservation
| Category | Shares Offered | % |
|---|---|---|
| Total | 2700000 | 100% |
| Anchor | 732000 | 27.11% |
| QIB | 540000 | 20% |
| HNI | 390000 | 14.44% |
| INDIVIDUAL | 900000 | 33.33% |
| Market Maker | 138000 | 5.11% |
Goldline Pharmaceutical About
IPO Details
| Total Issue Size | 27,00,000 shares (aggregating up to ₹11.61 Cr) |
| Fresh Issue | 27,00,000 shares (aggregating up to ₹11.61 Cr) |
| Face Value | ₹10/- Per Share |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE SME |
| Share Holding Pre Issue | 69,00,000 Equity Shares |
| Share Holding Post Issue | 96,00,000 Equity Shares |
| Reserved for Market Maker | 1,38,000 shares (aggregating up to ₹0.59 Cr) |
| Market Maker | Nirman Share Brokers |
Key Performance Indicators (KPI)
| KPI | Dec-25 | Mar-25 | Mar-24 |
|---|---|---|---|
| ROE | 21.02% | 35.83% | 31.31% |
| EPS (BASIC) | 3.22 | 4.10 | 3.01 |
| P/E Pre IPO | 10.47 | ||
| P/E Post IPO | 14.56 |
Company Financial (In ₹Crore)
| Period Ended | Dec-25 | Mar-25 | Mar-24 | Mar-23 |
|---|---|---|---|---|
| Assets | 27.40 | 26.28 | 22.93 | 19.39 |
| Total Income | 21.40 | 28.06 | 23.57 | 19.85 |
| Profit After Tax | 2.22 | 2.83 | 1.81 | 0.26 |
| EBITDA | 4.15 | 5.83 | 4.3 | 2.19 |
| NET Worth | 12.35 | 10.35 | 7.87 | 5.89 |
| Reserves and Surplus | 3.64 | 1.65 | 3.76 | 2.08 |
| Total Borrowing | 9.47 | 11.03 | 11.13 | 10.83 |
Peer Comparision (Valuation)
| Company | P/E (x) | Face value (₹) |
|---|---|---|
| Goldline Pharmaceutical Ltd. | 10.47 | 10 |
| Mono Pharmacare Ltd. | 7.57 | 10 |
| Chandra Bhagat Pharma Ltd. | 28.94 | 10 |
strength
Experienced promoters and management team: Leadership with pharmaceutical industry experience supports product positioning, market expansion and distributor relationships.
Asset-light and scalable business model: Outsourced manufacturing enables lower capital expenditure and operational flexibility while focusing on branding and sales growth.
Diversified therapeutic product portfolio: Presence across multiple specialties reduces dependence on a single therapeutic category and supports broader market reach.
Risk Factors
Dependence on Third-Party Manufacturers: The Company relies entirely on external manufacturers; consequently, any issues related to quality, regulatory compliance, or supply could adversely impact its operations and reputation.
Risk of Regulatory Compliance and Filings: Due to past delays and discrepancies in ROC filings, the Company may face fines or regulatory actions in the future.
Risk of Market Analysis and Product Selection: The growth of the business is contingent upon identifying successful pharmaceutical products; a failure to accurately assess market demand could negatively impact revenue and profitability.
About Company
Goldline Pharmaceuticals is engaged in the marketing and distribution of pharmaceutical products under the “Goldline” brand name.
The company operates through multiple product divisions including Goldline Pharma, Goldline Cardinal, Goldline Aayushman, Goldline InLife and Goldline Wellness, catering to diverse therapeutic specialties.
Its product portfolio covers medical fields such as cardiology, diabetology, pediatrics, orthopedics, neurology, gastroenterology, critical care and oncology supportive care.
The company follows an asset-light business model, where manufacturing is outsourced to third-party manufacturers while Goldline focuses on product selection, branding, marketing and distribution.
Products are distributed through a network of 15 manufacturers and 7 distributors, supplying retailers, wholesalers, hospitals and healthcare providers across states like Maharashtra, Madhya Pradesh, Odisha, Tamil Nadu, Rajasthan and Bihar.
The company emphasizes market research-driven product selection and specialty-focused branding strategies to expand its pharmaceutical presence.